We are live on ! Find out more
WHWK

Whitehawk Therapeutics

42 hedge funds and large institutions have $51M invested in Whitehawk Therapeutics in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more capital invested

Capital invested by funds: $34.3M → $51M (+$16.8M)

0.51% more ownership

Funds ownership: 3.74%4.25% (+0.51%)

0% more funds holding

Funds holding: 4242 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

Holders
42
Holders Change
Holders Change %
0%
% of All Funds
0.73%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
7
Reduced
10
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
-$4.52K -198 -94%
Bank of America
52
Bank of America
North Carolina
-$2.67K -117 -88%
OSAM
53
O'Shaughnessy Asset Management
Connecticut
-$206 -9 -38%

WHWK Hedge Fund Activity: Q2 2021 in Review

42 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2021, worth a combined $51M — up 49% from $34.3M a quarter earlier.

Fund positioning in WHWK was balanced in Q2 2021: 11 funds opened new positions, 11 closed out, 7 added to existing stakes and 10 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $6.85M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.67M sold.

  • 42 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $51M of Whitehawk Therapeutics stock for Q2 2021, up 49% quarter-over-quarter.
  • 11 funds opened new Whitehawk Therapeutics positions in Q2 2021 and 11 closed out, a net change of 0 holders.
  • The largest Whitehawk Therapeutics buyer in Q2 2021 was Avoro Capital Advisors, an estimated $6.85M added.
  • The largest Whitehawk Therapeutics seller in Q2 2021 was EcoR1 Capital, an estimated $2.67M sold.

Based on aggregated 13F filings for Q2 2021.